SG Americas Securities LLC Has $101,000 Stock Holdings in Perrigo Company plc (NYSE:PRGO)

SG Americas Securities LLC lowered its stake in Perrigo Company plc (NYSE:PRGO) by 15.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,137 shares of the company’s stock after selling 581 shares during the quarter. SG Americas Securities LLC’s holdings in Perrigo were worth $101,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Perrigo by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 14,328,895 shares of the company’s stock worth $510,968,000 after purchasing an additional 215,794 shares in the last quarter. BlackRock Inc. lifted its stake in Perrigo by 4.8% in the first quarter. BlackRock Inc. now owns 12,112,154 shares of the company’s stock valued at $465,469,000 after acquiring an additional 554,915 shares during the last quarter. Wolf Hill Capital Management LP grew its position in shares of Perrigo by 35.6% in the 2nd quarter. Wolf Hill Capital Management LP now owns 5,367,678 shares of the company’s stock valued at $182,233,000 after acquiring an additional 1,408,044 shares during the period. State Street Corp increased its stake in shares of Perrigo by 4.8% during the 1st quarter. State Street Corp now owns 4,270,353 shares of the company’s stock worth $164,110,000 after purchasing an additional 193,783 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Perrigo by 17.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 3,074,409 shares of the company’s stock valued at $118,149,000 after purchasing an additional 460,102 shares during the period. Institutional investors own 95.91% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Robert Willis purchased 6,000 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The stock was acquired at an average cost of $25.87 per share, for a total transaction of $155,220.00. Following the completion of the purchase, the executive vice president now owns 25,105 shares in the company, valued at approximately $649,466.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, EVP Robert Willis purchased 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The shares were bought at an average price of $25.87 per share, for a total transaction of $155,220.00. Following the completion of the transaction, the executive vice president now owns 25,105 shares of the company’s stock, valued at $649,466.35. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Patrick Lockwood-Taylor acquired 9,500 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The shares were purchased at an average cost of $26.54 per share, with a total value of $252,130.00. Following the transaction, the chief executive officer now directly owns 20,500 shares of the company’s stock, valued at $544,070. The disclosure for this purchase can be found here. Insiders have acquired a total of 17,990 shares of company stock worth $475,227 in the last quarter. Corporate insiders own 0.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on PRGO. Piper Sandler lifted their price target on Perrigo from $35.00 to $39.00 and gave the stock an “overweight” rating in a report on Monday, April 8th. JPMorgan Chase & Co. dropped their price target on Perrigo from $48.00 to $41.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 28th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $42.00 price objective on shares of Perrigo in a research report on Friday, April 12th. Finally, StockNews.com upgraded shares of Perrigo from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd.

Perrigo Trading Up 2.9 %

Shares of NYSE:PRGO opened at $30.80 on Friday. The stock has a market cap of $4.17 billion, a PE ratio of -308.00 and a beta of 0.64. The company has a quick ratio of 1.07, a current ratio of 1.79 and a debt-to-equity ratio of 0.76. Perrigo Company plc has a 12-month low of $25.77 and a 12-month high of $40.28. The business has a 50 day moving average of $30.62 and a 200-day moving average of $30.78.

Perrigo (NYSE:PRGO) last released its quarterly earnings results on Tuesday, February 27th. The company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. Perrigo had a positive return on equity of 7.34% and a negative net margin of 0.27%. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the previous year, the company posted $0.75 EPS. The firm’s quarterly revenue was up .1% on a year-over-year basis. As a group, equities research analysts forecast that Perrigo Company plc will post 2.55 earnings per share for the current year.

Perrigo Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 26th. Shareholders of record on Friday, March 8th were issued a $0.276 dividend. The ex-dividend date of this dividend was Thursday, March 7th. This represents a $1.10 dividend on an annualized basis and a yield of 3.58%. This is an increase from Perrigo’s previous quarterly dividend of $0.27. Perrigo’s payout ratio is currently -1,100.00%.

About Perrigo

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.